Literature DB >> 23160205

Immunology beats cancer: a blueprint for successful translation.

Drew M Pardoll1.   

Abstract

Immunology offers an unprecedented opportunity for the science-driven development of therapeutics. The successes of antibodies to the immunomodulatory receptor CTLA-4 and blockade of the immunoinhibitory receptor PD-1 in cancer immunotherapy, from gene discovery to patient benefit, have created a paradigm for driving such endeavors.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23160205      PMCID： PMC4659410          DOI： 10.1038/ni.2392

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


  30 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.

Authors:  H Nishimura; T Okazaki; Y Tanaka; K Nakatani; M Hara; A Matsumori; S Sasayama; A Mizoguchi; H Hiai; N Minato; T Honjo
Journal:  Science       Date:  2001-01-12       Impact factor: 47.728

4.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Authors:  Y Latchman; C R Wood; T Chernova; D Chaudhary; M Borde; I Chernova; Y Iwai; A J Long; J A Brown; R Nunes; E A Greenfield; K Bourque; V A Boussiotis; L L Carter; B M Carreno; N Malenkovich; H Nishimura; T Okazaki; T Honjo; A H Sharpe; G J Freeman
Journal:  Nat Immunol       Date:  2001-03       Impact factor: 25.606

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

Review 8.  Improved endpoints for cancer immunotherapy trials.

Authors:  Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd Old; Jedd Wolchok
Journal:  J Natl Cancer Inst       Date:  2010-09-08       Impact factor: 13.506

9.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.

Authors:  G J Freeman; A J Long; Y Iwai; K Bourque; T Chernova; H Nishimura; L J Fitz; N Malenkovich; T Okazaki; M C Byrne; H F Horton; L Fouser; L Carter; V Ling; M R Bowman; B M Carreno; M Collins; C R Wood; T Honjo
Journal:  J Exp Med       Date:  2000-10-02       Impact factor: 14.307

10.  B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells.

Authors:  S Y Tseng; M Otsuji; K Gorski; X Huang; J E Slansky; S I Pai; A Shalabi; T Shin; D M Pardoll; H Tsuchiya
Journal:  J Exp Med       Date:  2001-04-02       Impact factor: 14.307
View more
  79 in total

Review 1.  Sizing up the key determinants of the CD8(+) T cell response.

Authors:  David C Tscharke; Nathan P Croft; Peter C Doherty; Nicole L La Gruta
Journal:  Nat Rev Immunol       Date:  2015-10-09       Impact factor: 53.106

Review 2.  Current progress in immunotherapy for pancreatic cancer.

Authors:  Kelly Foley; Victoria Kim; Elizabeth Jaffee; Lei Zheng
Journal:  Cancer Lett       Date:  2015-12-23       Impact factor: 8.679

Review 3.  Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?

Authors:  Dev Karan
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

4.  Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic.

Authors:  Franck Housseau; Nicolas J Llosa
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

Review 5.  Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

Authors:  Niki Karachaliou; Aaron E Sosa; Miguel Angel Molina; Margarita Centelles Ruiz; Rafael Rosell
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

6.  Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.

Authors:  Dimitrios Mathios; Chul-Kee Park; Warren D Marcus; Sarah Alter; Peter R Rhode; Emily K Jeng; Hing C Wong; Drew M Pardoll; Michael Lim
Journal:  Int J Cancer       Date:  2015-07-28       Impact factor: 7.396

7.  Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors.

Authors:  Shipra Gandhi; Manu Pandey; Nischala Ammannagari; Chong Wang; Mark J Bucsek; Lamya Hamad; Elizabeth Repasky; Marc S Ernstoff
Journal:  Immunotherapy       Date:  2020-02-17       Impact factor: 4.196

Review 8.  The immunopathology of sepsis and potential therapeutic targets.

Authors:  Tom van der Poll; Frank L van de Veerdonk; Brendon P Scicluna; Mihai G Netea
Journal:  Nat Rev Immunol       Date:  2017-04-24       Impact factor: 53.106

9.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Authors:  Emanuela Romano; Monika Kusio-Kobialka; Periklis G Foukas; Petra Baumgaertner; Christiane Meyer; Pierluigi Ballabeni; Olivier Michielin; Benjamin Weide; Pedro Romero; Daniel E Speiser
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

Review 10.  Emerging nanotechnologies for cancer immunotherapy.

Authors:  Sourabh Shukla; Nicole F Steinmetz
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.